Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex May Rely More On Pfizer Support During P&U/Monsanto Integration

Executive Summary

The near-term performance of Searle/Pfizer's COX-2 inhibitor Celebrex (celecoxib) may rely more heavily on Pfizer's co-promotion efforts during a Pharmacia & Upjohn/Monsanto integration.
Advertisement

Related Content

Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says
Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says
Advertisement
UsernamePublicRestriction

Register

PS035364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel